Eger K - Search Results

1

Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro.

Gütschow M, Hecker T, Thiele A, Hauschildt S, Eger K. Gütschow M, et al. Among authors: eger k. Bioorg Med Chem. 2001 Apr;9(4):1059-65. doi: 10.1016/s0968-0896(00)00323-0. Bioorg Med Chem. 2001. PMID: 11354662

2

Michael adducts of palmitoylascorbic acid: effects on the oxidative burst of neutrophils and the production of tumor necrosis factor-alpha in monocytes.

Gütschow M, Hauschildt S, Benard S, Reichl S, Witt UG, Eger K, Arnhold J. Gütschow M, et al. Among authors: eger k. Pharmacology. 2002 Nov;66(3):162-8. doi: 10.1159/000063799. Pharmacology. 2002. PMID: 12372906

3

Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide.

Thiele A, Bang R, Gütschow M, Rossol M, Loos S, Eger K, Tiegs G, Hauschildt S. Thiele A, et al. Among authors: eger k. Eur J Pharmacol. 2002 Oct 25;453(2-3):325-34. doi: 10.1016/s0014-2999(02)02423-8. Eur J Pharmacol. 2002. PMID: 12398921

4

Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.

Lepper ER, Ng SS, Gütschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD. Lepper ER, et al. Among authors: eger k. J Med Chem. 2004 Apr 22;47(9):2219-27. doi: 10.1021/jm0304820. J Med Chem. 2004. PMID: 15084120

5

Studies on 2-benzyloxy-4H-3,1-benzoxazin-4-ones as serine protease inhibitors.

Gütschow M, Neumann U, Sieler J, Eger K. Gütschow M, et al. Among authors: eger k. Pharm Acta Helv. 1998 Jul;73(2):95-103. doi: 10.1016/s0031-6865(98)00003-x. Pharm Acta Helv. 1998. PMID: 9700938

6

2-(diethylamino)thieno1,3ŏxazin-4-ones as stable inhibitors of human leukocyte elastase.

Gütschow M, Kuerschner L, Neumann U, Pietsch M, Löser R, Koglin N, Eger K. Gütschow M, et al. Among authors: eger k. J Med Chem. 1999 Dec 30;42(26):5437-47. doi: 10.1021/jm991108w. J Med Chem. 1999. PMID: 10639285

7

A possible role of N-cadherin in thalidomide teratogenicity.

Thiele A, Thormann M, Hofmann HJ, Naumann WW, Eger K, Hauschildt S. Thiele A, et al. Among authors: eger k. Life Sci. 2000 Jun 16;67(4):457-61. doi: 10.1016/s0024-3205(00)00636-6. Life Sci. 2000. PMID: 11003055

8

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Ng SS, et al. Among authors: eger k. Cancer Res. 2003 Jun 15;63(12):3189-94. Cancer Res. 2003. PMID: 12810647

9

Synthesis and immunological activity of water-soluble thalidomide prodrugs.

Hess S, Akermann MA, Wnendt S, Zwingenberger K, Eger K. Hess S, et al. Among authors: eger k. Bioorg Med Chem. 2001 May;9(5):1279-91. doi: 10.1016/s0968-0896(00)00342-4. Bioorg Med Chem. 2001. PMID: 11377186

10

Inhibition of protein phosphatases by Michael adducts of ascorbic acid analogues with alpha,beta-unsaturated carbonyl compounds.

Witt UG, Schultz JE, Dölker M, Eger K. Witt UG, et al. Among authors: eger k. Bioorg Med Chem. 2000 Apr;8(4):807-13. doi: 10.1016/s0968-0896(00)00013-4. Bioorg Med Chem. 2000. PMID: 10819169

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters